Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MarketBeat

AirJoule Technologies: A Cool Shot at a Multibagger

AirJoule Technology is on track to comercialize its technology and unleadh a torrent of demand, hyper revenue growth, and a quick path to profits.

MarketBeat

Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears

Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.

MarketBeat

Oxford Instruments H2 Earnings Call Highlights

Oxford Instruments (LON:OXIG) said it delivered a stronger second half after a difficult start to the year, as improving demand from commercial semiconductor customers helped offset weaker academic markets and geopolitical uncertainty. Chief Executive Richard Tyson told investors the company was “r

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near

Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Yuval Cohen outlined the company’s near-term clinical readout schedule and development plans for its two lead drug candidates during a Jefferies fireside chat hosted by biotech analyst Amin Makarem. Cohen said the Norwood, Massachusetts-based dru

MarketBeat

Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans

Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft. Sorensen said Hemab is pursuing a strategy to build “a multiple product

MarketBeat

Zepp Health Q1 Earnings Call Highlights

Zepp Health (NYSE:ZEPP) reported a stronger start to 2026, with management pointing to new Amazfit product launches, a higher-end product mix and expanding positioning in hybrid training as the main drivers of first-quarter growth. On the company’s earnings call, Founder and Chief Executive Officer

MarketBeat

CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans

CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion. Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls

Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT. Mark Singleton, Bioventus’ senior vice president and chief financi

MarketBeat

Vail Resorts Q3 Earnings Call Highlights

Vail Resorts (NYSE:MTN) said historically poor weather across the Western United States continued to weigh on fiscal third-quarter results, pressuring visitation and revenue at its mountain resorts while management emphasized that its advance commitment pass model and cost controls helped cushion th

MarketBeat

Gloo Q1 Earnings Call Highlights

Gloo (NASDAQ:GLOO) reported fiscal first-quarter revenue and adjusted EBITDA ahead of its own guidance and Wall Street consensus, as executives pointed to momentum from large strategic customers, recent acquisitions and growing demand for AI-enabled technology and marketing tools across faith-based

MarketBeat

Mama's Creations Q1 Earnings Call Highlights

Mama's Creations (NASDAQ:MAMA) reported sharply higher first-quarter fiscal 2027 results, with management pointing to new retail placements, the Crown I acquisition and broader customer growth as the main drivers, even as gross margins were pressured by launch-related costs. Chairman and CEO Adam L

MarketBeat

Mission Produce Q2 Earnings Call Highlights

Mission Produce (NASDAQ:AVO) said its fiscal second quarter was pressured by an unusually high-supply avocado market, particularly from Mexico, which drove prices to multi-year lows and compressed margins despite higher avocado volumes. President and Chief Executive Officer John Pawlowski, who form

MarketBeat

Motorcar Parts of America Q4 Earnings Call Highlights

Motorcar Parts of America (NASDAQ:MPAA) reported stronger fiscal fourth-quarter and full-year results, with management pointing to sales momentum, new business commitments and improving profitability as key drivers heading into fiscal 2027. Chairman, President and Chief Executive Officer Selwyn Jof

MarketBeat

Amprius Insiders Are Selling: Should Investors Be Worried?

Amprius Technology is on track to set a new all-time high later this year after it reports Q2 results and guidance. Short interest suggests a squeeze is possible.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Graham Q4 Earnings Call Highlights

Graham (NYSE:GHM) reported record fiscal 2026 revenue, orders and backlog, with management pointing to strong demand in defense, improving momentum in space and contributions from recent acquisitions as the company enters fiscal 2027. On the company’s fiscal fourth-quarter earnings call, President

MarketBeat

Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead

Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate

MarketBeat

Optical Cable Q2 Earnings Call Highlights

Optical Cable (NASDAQ:OCC) reported sharply higher fiscal second-quarter sales and profit, with management citing strength in enterprise, data center and severe-duty markets, as well as improved manufacturing leverage. On the company’s fiscal 2026 second-quarter earnings call, President and Chief E

MarketBeat

FuelCell Energy Q2 Earnings Call Highlights

FuelCell Energy (NASDAQ:FCEL) reported a wider second-quarter loss for fiscal 2026 as a non-cash impairment tied to its Groton Navy project weighed on results, while management emphasized a sharply expanding sales pipeline tied largely to data center and artificial intelligence-related power demand.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Duluth Q1 Earnings Call Highlights

Duluth (NASDAQ:DLTH) reported a narrower first-quarter loss and higher gross margins as management said its ongoing effort to reduce promotions, rationalize inventory and cut costs continued to reshape the apparel retailer’s financial profile. President and Chief Executive Officer Stephanie Puglies

MarketBeat

Gamehaus Q3 Earnings Call Highlights

Gamehaus (NASDAQ:GMHS) reported third-quarter fiscal 2026 revenue above its prior guidance range while management emphasized improving profitability, tighter marketing discipline and growing use of direct-to-consumer payments and artificial intelligence across the business. On the company’s earning

MarketBeat

VinFast Auto Q1 Earnings Call Highlights

VinFast Auto (NASDAQ:VFS) reported sharply higher first-quarter 2026 vehicle deliveries and revenue, while management said gross margin was pressured by accounting impacts tied to an expanded free-charging program and other adjustments. On the company’s earnings call, Chairman Pham Nhat Quan Anh sa

MarketBeat

What's Make of Macy's: Berkshire Hathaway's Latest Buy

Berkshire Hathaway just turned over a rock that many would not think to look under. See the status of its latest portfolio addition, retail giant Macy's.

MarketBeat

Campbell's Q3 Earnings Call Highlights

Campbell's (NASDAQ:CPB) executives used the company’s third-quarter fiscal 2026 earnings question-and-answer session to outline a more cautious operating backdrop heading into fiscal 2027, citing potential incremental inflation tied to higher oil prices, continued pressure in snacks and a focus on b

MarketBeat

Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win

Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secon

MarketBeat

AstroNova Q1 Earnings Call Highlights

AstroNova (NASDAQ:ALOT) reported higher fiscal first-quarter revenue and improved profitability, driven primarily by strength in its Aerospace segment, as management said the company is benefiting from commercial aircraft demand, growing orders and internal cost controls. On the company’s fiscal 20

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.